Mason Street Advisors LLC boosted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 1.6% during the first quarter, Holdings Channel reports. The firm owned 19,129 shares of the medical equipment provider’s stock after buying an additional 300 shares during the period. Mason Street Advisors LLC’s holdings in ABIOMED were worth $2,395,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in ABMD. Creative Planning boosted its stake in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 129 shares during the period. Advantage Investment Management LLC purchased a new stake in ABIOMED during the fourth quarter valued at about $150,000. Virginia Retirement Systems ET AL purchased a new stake in ABIOMED during the first quarter valued at about $200,000. Palladium Partners LLC purchased a new stake in ABIOMED during the first quarter valued at about $211,000. Finally, Tyers Asset Management LLC purchased a new stake in ABIOMED during the fourth quarter valued at about $220,000. 92.67% of the stock is owned by institutional investors and hedge funds.
ABIOMED, Inc. (NASDAQ:ABMD) traded up 0.89% during midday trading on Friday, hitting $134.43. 236,498 shares of the stock traded hands. ABIOMED, Inc. has a one year low of $94.81 and a one year high of $134.91. The company’s 50-day moving average is $128.27 and its 200-day moving average is $117.69. The company has a market cap of $5.86 billion, a PE ratio of 114.90 and a beta of 0.51.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, May 4th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. The firm had revenue of $124.68 million for the quarter, compared to the consensus estimate of $122.82 million. During the same quarter in the previous year, the firm posted $0.24 EPS. The firm’s quarterly revenue was up 32.7% on a year-over-year basis. Equities research analysts expect that ABIOMED, Inc. will post $1.84 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.mideasttime.com/abiomed-inc-abmd-stake-raised-by-mason-street-advisors-llc/1708565.html.
ABMD has been the subject of several recent analyst reports. TheStreet raised shares of ABIOMED from a “c+” rating to a “b-” rating in a research report on Tuesday, February 21st. Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “hold” rating in a research report on Monday, January 30th. Leerink Swann lifted their price objective on shares of ABIOMED from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, March 30th. Finally, Piper Jaffray Companies raised shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 price objective for the company in a research report on Thursday, April 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $151.00.
In other ABIOMED news, VP Andrew J. Greenfield sold 10,000 shares of the firm’s stock in a transaction on Friday, March 17th. The shares were sold at an average price of $124.00, for a total transaction of $1,240,000.00. Following the completion of the transaction, the vice president now directly owns 66,307 shares of the company’s stock, valued at approximately $8,222,068. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Michael G. Howley sold 600 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $132.84, for a total transaction of $79,704.00. Following the transaction, the vice president now directly owns 48,305 shares of the company’s stock, valued at $6,416,836.20. The disclosure for this sale can be found here. Insiders have sold a total of 63,629 shares of company stock worth $8,312,580 in the last ninety days. 10.00% of the stock is currently owned by insiders.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.